Dr. Qunying Yang 杨群英
Chief Physician
Department of Neurosurgery, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and individualized comprehensive treatment for brain gliomas, germ cell tumors, medulloblastoma, primitive neuroectodermal tumors, neuroblastoma, primary CNS lymphoma, malignant meningioma, ependymoma, and brain metastases.
Dr. Yang is a Chief Physician with a medical doctorate at Sun Yat-sen University Cancer Center. In 2012, Dr. Yang completed clinical training in neuro-oncology at the University of Texas M.D. Anderson Cancer Center. In 2013, Dr. Yang was a visiting scholar at the Prince of Wales Hospital, Chinese University of Hong Kong. With over ten years of experience, Dr. Yang specializes in chemotherapy for nervous system tumors and has participated in multiple clinical trials.
Professional roles
- Member, Neuro-Oncology Professional Committee, China Anti-Cancer Association
- Member, Neuro-Oncology Professional Committee, Guangdong Anti-Cancer Association
- Member, Chinese Medical Association (Oncology Chemotherapy)
- Member, Chinese Medical Doctor Association (Neurosurgery)
Name order: in Chinese the family name comes first (Yang Qunying). Papers usually list the name as Qunying Yang or Yang Q.
Selected publications
40 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Sci, 2023 (senior author): Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. PubMed 36853018
- Front Cell Dev Biol, 2022 (senior author): A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma. PubMed 36092717
- Front Pharmacol, 2021 (first author): Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis. PubMed 35002738
- Front Pharmacol, 2020 (senior author): External Validation of a Nomogram and Risk Grouping System for Predicting Individual Prognosis of Patients With Medulloblastoma. PubMed 33343359
- Onco Targets Ther, 2015 (first author): Profile of nimotuzumab in the treatment of high-grade glioma. PubMed 25926743
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion